Fatty liver disease (FLD) is frequently observed in HIV-infected patients. Obesity and type 2 diabetes mellitus (T2DM) are strongly associated with FLD. Because genetic variants within the fat mass and obesity-associated (FTO) gene have been associated with both pathologies, our aim was to evaluate the association of single nucleotide polymorphisms (SNPs) within the FTO, previously related to obesity or T2DM, with FLD in HIV-infected patients.
Introduction
Fatty liver disease (FLD), which has an estimated prevalence of 30-40% in HIV-infected patients [1] [2] [3] , is a well-recognized cause of cirrhosis and hepatocellular carcinoma [4] . Obesity has been identified as the main risk factor for FLD in HIV-infected patients [1] [2] [3] 5] . Other factors, such as insulin resistance, the metabolic syndrome, hepatitis C virus (HCV) genotype 3 coinfection and some antiretroviral drugs, have also been associated with FLD in HIV-infected patients, although these relationships have not been widely reproduced [5] [6] [7] [8] .
Genetic factors have been linked to FLD in HIV-uninfected patients [9-13], suggesting a role for the individual genetic background in the development of FLD. Recently, some of these genetic associations have been replicated in HIV-infected patients [14] , suggesting that genetic variations may also have a role in the emergence of FLD in the setting of HIV infection.
The fat mass and obesity-associated gene (FTO), located at 16q12-24, was identified as a susceptibility gene for obesity and type 2 diabetes mellitus (T2DM) [15] [16] [17] . Subsequently, various single nucleotide polymorphisms (SNPs) within the FTO gene, mainly belonging to the cluster located in intron 1, have been related to obesity and T2DM world-wide [18] . FTO encodes an RNA demethylase whose major substrate is N6-methyladenosine [19] and which is involved in post-transcriptional regulation. Although FTO seems to have an important role in metabolic homeostasis [18] , the exact mechanism of the contribution of this gene to obesity or T2DM pathogenesis is unclear. Recently, it has been reported that increased levels of FTO expression are associated with nonalcoholic FLD (NAFLD) in a rat model and that FTO overexpression increases lipogenesis and oxidative stress in human hepatocyte cells [20] . These findings suggest that variations within the FTO gene could be associated with FLD.
The aim of this study was to evaluate the association of FTO SNPs, previously related to obesity or T2DM, with FLD in HIV-infected patients.
Patients and methods

Patients and study design
This was a cross-sectional study. All HIV-infected individuals who consecutively attended out-patient clinics in four university hospitals in Spain between November 2011 and December 2013 were invited to participate if they were aged 18 years or older and Caucasian. All patients underwent transient elastography (TE) with controlled attenuation parameter (CAP) examination during a single visit previously scheduled as a routine follow-up visit. Clinical data were collected during the same visit. In all patients, blood samples were collected for routine laboratory and genetic determinations.
Patients were excluded if they belonged to the same family or were pregnant, if hepatic TE was not reliable or if the genotyping rate was < 100%. A total of 421 participants were randomly selected for inclusion in the sample used for testing the association between FTO SNPs and FLD (the discovery sample). The remainder of the patients constituted the validation sample.
Overweight was defined as a body mass index (BMI) > 25 kg/m 2 and high alcohol intake was defined as > 50 g/day [21] .
Transient elastography examination
TE with CAP measurements was performed in fasting patients by an experienced operator at each participating centre using a commercially available device (FibroScan 502; Echosens, Paris, France). TE examinations were conducted as stated elsewhere [1] . According to previously reported standards, examinations with 10 successful shots, an interquartile range (IQR) for liver stiffness < 30% of the median value and a success rate of ≥ 60% were included [22] .
SNP selection and genotyping
FTO SNPs previously found to be associated with metabolic syndrome (rs9940128) [23] and T2DM (rs8050136, rs9939609 and rs11642841) [24] [25] [26] [27] [28] [29] [30] [31] in genome-wide association studies (GWASs) performed in the general population were included in this study. In addition, the rs12743824 genetic marker, linked to the lipid phosphate phosphatase-related protein type 4 (LPPR4) gene, and previously associated with FLD in our population [14] , was also included.
DNA was extracted from whole blood, frozen at À80°C, using the Quick Pure Blood DNA extraction kit (Macherey-Nagel, D€ uren, Germany) following the manufacturer's instructions. SNP genotyping were performed using a custom Golden Gate protocol (Illumina, San Diego, CA). SNP genotyping services were provided by the Spanish Centro Nacional de Genotipado (CGEN-ISCIII; http://www.usc.es/cegen/). In the validation sample, genotyping of rs9940128 and rs12743824 was carried out using the Taqman OpenArray genotyping system (Applied Biosystems, Foster City, CA, USA) in accordance with the manufacturer's instructions. In this case, SNP genotyping services were provided by the Instituto de Biomedicina de Sevilla (IBIS; www.ibis-sevilla.es/).
Statistical analyses
The primary outcome variable was the presence of FLD. FLD was defined as a CAP value ≥ 238 dB/m. This cutoff value has been described as the optimal value with which to discriminate FLD affecting ≥ 10% of hepatocytes [32] .
The online resource at the Institute for Human Genetics, Munich, Germany (http://ihg.gsf.de) was used in the comparison of genotypic frequencies between groups to determine P-values, odds ratios (ORs), 95% confidence intervals (CIs) and HardyÀWeinberg equilibrium.
HAPLOVIEW software v.4.1 [33] was employed to calculate linkage disequilibrium (LD) values between SNPs. Haplogenotypes were imputed for each individual using PLINK software v.1.0.7. [34] .
Quantitative variables were expressed as median (quartile 1-quartile 3) and categorical variables as absolute frequency (percentage). Quantitative variables in discovery and validation samples were compared by means of Student's t-test (for data that were normally distributed) or the Mann-Whitney U-test (for data that were not normally distributed). Comparisons between categorical variables were performed using the Pearson chi-square test. Factors associated with the primary outcome variable in the univariate analysis with a P-value ≤ 0.2 were included as covariables, as well as age and gender, in logistic regression models to detect independent associations with FLD. The BreslowÀDay test was employed to test homogeneity of the ORs in the stratified analysis. Statistical significance was established at a P-value < 0.05. These statistical analyses were performed using SPSS software 22.0 (IBM Corporation, Somers, NY, USA).
Ethics statement
This study was in compliance with national legislation and was performed according to the ethical guidelines of the Declaration of Helsinki. The Ethics Committee of the Hospital Universitario de Valme approved this study. Written consent was obtained from all participants before sampling.
Results
Study population
A total of 643 HIV-infected individuals were selected for this study. However, 16 individuals were excluded: 13 (2.0%) of them because of unreliable TE evaluation and three (0.5%) because of a low genotyping rate. Therefore, 627 individuals constituted the study population. FLD was observed in 267 patients (45.6%). Of these patients, 39 (6.2%) showed a BMI ≥ 30 and 24 (3.8%) had a fasting plasma glucose concentration ≥ 126 mg/dL. Anti-HCV antibodies were observed in 510 patients (81.3%), but only 338 (53.9%) showed detectable plasma HCV RNA. Two hundred and thirty-five individuals (46.1%) of those seropositive for HCV had received therapy against HCV. One hundred and six (45.1%) of those who had been treated for HCV infection achieved a sustained virological response. The main characteristics of the study population are summarized in Table 1 .
Analyses of the association between FTO polymorphisms and FLD
Data for the first 421 enrolled individuals (the discovery sample) were used to test the association between the selected FTO SNPs and FLD. FLD was present in 175 (41.5%) HIV-infected individuals. The genotypic distributions of these SNPs are displayed in Table 2 . All of them were in accordance with HardyÀWeinberg equilibrium (P > 0.187 in all cases). Because the rs8050136 and rs9939609 SNPs showed identical genotypic distributions in the study population (Table 2) , rs9939609 was selected as a representative genetic marker of this region for subsequent analyses.
Two SNPs (rs9939609 and rs9940128) associated with FLD following a recessive genetic model (Table 2) . Thus, compared with individuals without FLD, a significantly higher proportion of individuals with FLD carried the AA genotype for rs9940128 (P = 0.016; OR: 1.84; 95% CI: 1.11-3.06) and for rs9939609 (P = 0.028; OR: 1.79; 95% CI: 1.06-3.03) ( Table 2 ).
The FTO SNPs rs9940128, rs9939609 and rs11642841 extend over 44 kb, encompassing a genetic region in high LD (d' > 0.8) (Fig. 1) . When haplo-genotypes were imputed using PLINK software, a significantly higher proportion of AAA/AAA carriers was not observed in patients with FLD compared with those without FLD (P = 0.105; OR: 1.61; 95% CI: 0.91-2.89) (Fig. 2) .
Validation study
The results obtained in the discovery sample indicated that rs9940128 was the genetic factor most strongly associated with FLD and that it could be considered a representative marker of this genomic region. Therefore, it was selected for validation in an additional sample. Two hundred and six HIV-infected individuals were included in this new study. Of these, 92 (44.7%) showed FLD. The genotypic distribution of rs9940128 in the group of individuals without FLD was 16 (14.0%) AA, 57 (50.0%) AG and 41 (36.0%) GG. The corresponding figures in the FLD group were 23 (25.0%) AA, 41 (44.6%) AG and 28 (30.4%) GG. . These genotypic distributions were also in accordance with HardyÀWeinberg equilibrium (P > 0.3). Again, compared with patients without FLD, a significantly higher proportion of individuals with FLD carried the AA genotype (P = 0.046; OR: 2.04; 95% CI: 1.01-4.14). Table 3 displays the variables that showed a univariate association with FLD in the total study population. In the multivariate analysis, the rs9940128 AA genotype, fasting plasma glucose level > 100 mg/dl, being overweight, and the presence of the rs12743824 A allele were identified as independent risk factors for FLD (Table 3) . In order to confirm that the association of rs9940128 with FLD was not confounded by BMI, we also performed an analysis stratified by BMI with a cut-off of 25 kg/m 2 .
Multivariate analysis
This analysis did not show significant differences in the effect size of this SNP across strata (BreslowÀDay P-value = 0.738). Of note, in nonoverweight individuals (BMI < 25 kg/m 2 ), the frequency of FLD among rs9940128 AA carriers was 44.8% (26 of 58 individuals) and that in patients with genotypes other than rs9940128 AA was 28.6% (91 of 318 individuals) (P = 0.014; OR: 2.03; 95% CI: 1.14-3.60). Similar results were obtained when the patients were stratified by plasma glucose level with a cut-off of 100 mg/dL. Again, there were no significant differences in the effect of this SNP across strata (BreslowÀDay Pvalue = 0.869). In this case, in the group of patients with plasma glucose < 100 mg/dL, the frequency of FLD among rs9940129 AA carriers was 48.5% (33 out 68 individuals), and that in patients with genotypes other than rs9940129 AA was 34.8% (125 of 359 individuals) (OR: 1.76; 95% CI: 1.05-2.98; P = 0.032).
Finally, the effect of this SNP in patients with and without active HCV infection was also similar (BreslowÀDay P-value = 0.469).
Discussion
In the present study, we found that genetic variations in the FTO gene were associated with FLD in HIV-infected patients. Importantly, this relationship was independent of other determinants of FLD, particularly BMI. Thus, the mechanism underlying the association of FTO SNPs with FLD does not seem to be mediated by obesity. Therefore, and taking into account that this gene has not been associated with FLD in the GWASs performed in general populations of different ethnicities [9-13], genetic variations within FTO could be involved in the pathogenesis of FLD only in the setting of HIV infection.
The FTO gene is widely expressed, mainly in the hypothalamus and pancreatic islets, but also in other tissues such as adipose tissue, the liver and skeletal muscle [18] . FTO overexpression has been associated with obesity [35] , T2DM [36] and NAFLD [20, 37] . In NAFLD, FTO seems to alter the mitochondrial respiratory chain, inducing oxidative stress and lipid accumulation [20] and disturbing glucose metabolism by FoxO1 (forkhead transcription factor O1) [37] in human hepatocyte cell lines and animal models. The effects of FTO variations on FTO expression are not clear. Some studies have shown increased FTO expression to be associated with some FTO genotypes [38] . However, other studies have failed to reveal any influence of the FTO genotype on the mRNA level of FTO [18, 36] . Another possible mechanism linking FTO genetic variations and FLD is the interaction between the FTO cluster region of intron 1 and the iroquois homeobox 3 (IRX3) gene. All SNPs evaluated herein are located within the FTO cluster region of intron 1. This region has been functionally connected with IRX3 gene expression [39] . In this regard, lack of irx3 expression in a mouse model induces resistance to hepatic steatosis [39] . Although the role of FTO SNPs in obesity has been widely studied [18, 40] , the potential influence of these SNPs on FLD has scarcely been investigated. Recently, a significant association of the A allele of FTO rs9939609 with NAFLD has been reported in Chinese HIV-uninfected patients. Nevertheless, this association disappeared after adjustment by BMI, indicating that the effect of this SNP on FLD could be mediated by obesity in this population [41] . In contrast, our study, performed in a Caucasian population of HIV-infected patients, showed an independent association of FTO SNPs with FLD after adjustment for metabolic factors including BMI. Moreover, in an analysis restricted to individuals without overweight or obesity, we found that those variations within the FTO gene continued to be associated with FLD. Discordant results between Chinese and Caucasian populations must not be attributable to genetic differences in this region because the cluster of intron 1 of FTO in East Asian populations shows similar LD (r 2 > 0.80) and extension (~46 kb) to those observed in European populations [40] . Therefore, it is possible that the independent association of FTO SNPs with FLD could be restricted to the HIV-infected population. Cosistent with this hypothesis, a recent study examining the effect of FTO rs9939609 on several outcomes in HIV/HCV-coinfected patients found that the AA genotype was independently associated with hepatic steatosis [42] . rs9939609 has been widely studied because it was the first variant associated with the risk of developing obesity [17] . In our study, the inclusion of more SNPs allowed us to identify FTO rs9940128 as the best predictive variant of this gene for FLD in our population, suggesting that this SNP is in higher LD with the causative one than the rs9939609 SNP. This was also supported by the fact that the association of FTO rs9940128 with FLD was stronger than that observed for any of the haplo-genotypes defined by the three SNPs analysed herein. The results of the present study could have potential clinical implications. FLD and BMI are strongly associated. Therefore, clinicians usually consider the diagnosis of FLD mainly in obese or overweight patients. However, we found that genetic variations within the FTO gene were associated with FLD among HIV-infected individuals with normal BMI. Given that NAFLD is less commonly suspected among HIV-infected patients without overweight, FTO rs9940128 genotyping could be used as a tool to identify those at risk of FLD.
This study has some limitations. First, the diagnosis of FLD was based on TE with CAP determination instead of histological examination by liver biopsy. Liver biopsy is the gold standard technique for FLD diagnosis, but it is limited because of the invasive nature of the technique. This makes biopsy inappropriate for screening for FLD in patients without evidence of liver disease obtained by other means, as is the case in many patients with FLD. In spite of this, CAP determination has been shown to be an adequate noninvasive alternative for the diagnosis of FLD [32, 43] . Secondly, a relatively small number of HIV-monoinfected patients were included in this study. Therefore, a study in a larger cohort of HIV-monoinfected patients is warranted to confirm our results. Nevertheless, this is the largest study analysing the association between FTO SNPs and FLD in the HIV infection setting reported to date. Thirdly, alcohol intake was not associated with FLD in our sample. This has also been observed in similar studies performed in similar populations [1, 44] . Because alcohol intake was self-reported, we cannot rule out the possibility that patients underreported alcohol consumption. Finally, none of the antiretroviral treatments that were being received by the patients was associated with FLD. However, we have not studied the association between FLD and the duration of exposure to these treatments. In a study performed in a very similar population, which included a similar number of individuals, no relationship was detected between FLD and antiretroviral treatment ever prescribed or the length of exposure to those treatments [1] . The same results were found in a meta-analysis performed in HCV/HIV-coinfected individuals [44] .
In summary, we identified FTO rs9940128 polymorphism as an additional genetic factor independently associated with FLD in HIV-infected patients. In view of the size of its effect on the likelihood of FLD, this FTO genetic variant could be considered as a potential clinical genetic marker of this disease. Nevertheless, the role of FTO variants in identifying HIV-infected individuals at risk for developing FLD needs further evaluation. 
